Dr. Delaney examines cord blood cells she is expanding.
Photo by Fred Hutch
Fred Hutch is a world leader in hematopoietic (blood) stem cell transplantation and its use as a treatment for blood cancers, hematological diseases and other conditions. Worldwide, more than a million patients have turned to transplantation to save their lives. For thousands transplantation is not an option because they don't have a genetically matched donor.
Our work began by pioneering bone marrow transplantation and it continues today in our breakthrough research of cord blood transplantation. Cord blood saves lives, and research in the Delaney Lab is bringing powerful cord blood–based therapies to more people who need a new lifesaving option.
Improving patient options and treatment outcomes
The Hutch’s Cord Blood Program was launched in 2006. Since then, we have performed more than 300 transplants in patients with malignant and non-malignant diseases who range in age from less than 1 year to 71 years.
Dr. Colleen Delaney, Director for the Fred Hutch Cord Blood Program, developed a method for multiplying, or expanding, key stem cells in cord blood, with the goal of extending the use of this expanded cord blood product into something that could be ordered up by doctors at a moment’s notice. Her vision is to create a therapy that can become FDA approved and be given to patients around the world.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.